Life sciences giant Thermo Fisher Scientific has agreed to acquire clinical trials software company Clario for a consideration of up to $9.4bn.

Through the Center for Multisite Studies, NYU Langone can help manage a coordinating center for multisite studies.

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is gen ...

As the world becomes more digital, clinical research is evolving. One major change is the rise of decentralized clinical ...

Key opportunities in the clinical trial platform market include leveraging AI and machine learning for enhanced trial design ...

Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion in cash and ...

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced a poster presentation at the ...

Hitachi High-Tech Corporation ("Hitachi High-Tech"), has launched the SU9600, which allows for highly accurate and precise ...

Metagenomics is the study of all organisms present in a particular environment, such as soil, water, or the human body. A key ...

Health systems and insurance companies are using artificial intelligence to analyze CT scans and MRIs, update electronic ...

Intensity Therapeutics, Inc. ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent ...